Inclusion Criteria:

          1. Patients 18 years of age or older with advanced CML (CML-AP, CML-BP and Philadelphia
             chromosome-positive acute leukemia) or refractory chronic phase CML are eligible, as
             defined as follows: The phase I portion of the study will be conducted first in
             advanced phase (accelerated phase CML, blast phase CML or Philadelphia-positive acute
             leukemia) patients. Once MTD is identified, a cohort of 6 patients with CML chronic
             phase who have failed prior therapy with at least two tyrosine kinase inhibitor will
             be treated at the MTD to determine if this dose is also acceptable for chronic phase
             patients. The phase II will be conducted in two treatment arms as follows: Treatment
             Arm A (Advanced phase disease) and treatment Arm B (Therapy for CP-CML
             refractory/resistant/suboptimally responding to at least two prior TKI's)

          2. (Cont - Inclusion Criteria #1) CML-AP is defined by the presence of one of the
             following: a. 15-29% blasts in peripheral blood (PB) or bone marrow (BM), b.>20%
             basophils in PB or BM, c.>30% blasts plus promyelocytes (with blasts <30%) in PB or
             BM, d.<100 x109/L platelets unrelated to therapy, or Clonal cytogenetics evolution
             (i.e., the presence of cytogenetic abnormalities other than the Philadelphia
             chromosome) except if only present at the time of diagnosis and not associated with
             other features of accelerated phase. CML-BP is defined by the presence of >/=30%
             blasts in the bone marrow and/or peripheral blood or the presence of extramedullary
             disease, with myeloid or lymphoid blast morphology. Philadelphia-chromosome acute
             leukemias are eligible and defined by >/=20% blasts in the peripheral blood or bone
             marrow at the time of diagnosis.

          3. Patients with advanced phase CML or acute leukemia must have failed at least one prior
             TKI. Patients with chronic phase CML must have failed, have resistance or suboptimal
             response to at least two tyrosine kinase inhibitors, or have intolerance to two prior
             tyrosine kinase inhibitors. For patient with prior intolerance, they should have
             received at least 2 TKI and experienced intolerance to one TKI and
             resistance/suboptimal

          4. (Cont - Inclusion Criteria #3) a. Failure to tyrosine kinase inhibitors will be
             defined per European-Leukemia-Net (ELN) recommendations b.Resistance or suboptimal
             response to at least two prior Abl-kinase inhibitor, specifically: i.Chronic-phase
             with resistance to imatinib, dasatinib, nilotinib, bosutinib or ponatinib defined as
             1. Loss of CCyR at any time or failure to achieve CCyR after >/=18 months 2. Loss of
             MCyR at any time or failure to achieve PCyR after >/=12 months 3. Failure to achieve
             any CyR (ie, >/= 65% Ph+) after >/= 6 months 4. Hematologic relapse or failure to
             achieve CHR after >/=3 months ii. Chronic-phase with suboptimal response to imatinib,
             defined as 1. Failure to achieve PCyR after >/= 6 months 2. Failure to achieve CCyR
             after >/=12 months iii. Chronic-phase with suboptimal response to nilotinib,
             bosutinib, dasatinib or ponatinib, defined as 1. Failure to achieve PCyR after >/= 3
             months 2. Failure to achieve CCyR after >/= 6 months of therapy

          5. Patients with cytogenetic BCR-Abl variants and additional chromosomal abnormalities
             ('clonal evolution') will be eligible. Cytogenetics to be performed, but results are
             not required to start therapy in patients with hematologic progression

          6. Patients who have failed nilotinib, including those who are refractory to nilotinib at
             any dose or have relapsed on nilotinib at any dose will be eligible for the study.
             Patients currently on nilotinib will continue on their prescribed dose of nilotinib
             and MEK-162 will be added based on the current cohort level in phase I or at the
             established MTD in phase II. In the instance the nilotinib dose is greater than the
             current cohort (in phase 1) or the MTD (in phase 2) patients will be dose reduced to
             the dosage as prescribed by protocol and then dose escalated as allowed in protocol at
             the PIs discretion.

          7. For the phase I portion of the study, patients who had received prior therapy with
             nilotinib should have been able to tolerate the dose equivalent to the starting dose
             of nilotinib in the dose level at which the patient is being entered. Patients who
             previously received nilotinib but never at the dose being proposed are eligible
             provided they tolerated the maximum dose they were prescribed with no grade 3 or 4
             toxicity not responding to optimal management.

          8. Patients must have been off all prior therapy for CML for 2 weeks prior to start of
             study therapy and recovered from the toxic effects of that therapy. Exceptions to
             these are hydroxyurea and TKIs (including but not limited to imatinib, nilotinib,
             dasatinib, ponatinib and bosutinib), which should be discontinued ≥48 hrs prior to the
             start of therapy. Patients who are receiving nilotinib prior to enrollment do not have
             to discontinue this agent prior to start of study therapy

          9. Eastern Cooperative Oncology Group (ECOG) performance status </=2

         10. Men and women of childbearing potential should practice effective methods of
             contraception. Men and women of childbearing potential are defined as: a male that has
             not been surgically sterilized or female that has not been amenorrheic for at least 12
             consecutive months or that has not been surgically sterilized. Patients must use birth
             control during the study and for 3 months after the last dose of study drug if they
             are sexually active.

         11. Adequate organ function: Serum creatinine </=2.0 mg/dl or creatinine clearance >/=60
             mL/min, Direct bilirubin </=2.0xULN (unless considered due to leukemia involvement),
             Alanine aminotransferase (ALT) </=2.5xULN (</=5.0xULN if considered due to leukemic
             involvement.)

         12. Adequate cardiac function: left ventricular ejection fraction (LVEF) >/= 50% as
             determined by a multigated acquisition (MUGA) scan or echocardiogram, QTc interval </=
             480 ms;

         13. Women of childbearing potential must have a pregnancy test at screening.

         14. Signed informed consent.

        Exclusion Criteria:

          1. Impaired cardiac function including any one of the following: a. Inability to monitor
             the QT interval on ECG b. Congenital long QT syndrome or a known family history of
             long QT syndrome. c. Clinically significant resting brachycardia (<45 beats per
             minute) d. QTc > 480 msec on baseline ECG. If QTc >450 msec and electrolytes are not
             within normal ranges, electrolytes should be corrected and then the patient
             re-screened for QTc e. Impaired cardiovascular function or clinically significant
             cardiovascular diseases, including any of the following: History of acute coronary
             syndromes (including myocardial infarction, unstable angina, coronary artery bypass
             grafting, coronary angioplasty, or stenting) <6 months prior to screening, Symptomatic
             chronic heart failure, history or current evidence of clinically significant cardiac
             arrhythmia and/or conduction abnormality <6 months prior to screening except atrial
             fibrillation and paroxysmal supraventricular tachycardia

          2. History of Gilbert's syndrome.

          3. Uncontrolled arterial hypertension despite medical treatment

          4. Prior therapy with a MEK- inhibitor

          5. History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
             or hypercoagulability syndromes)

          6. History of retinal degenerative disease;

          7. Patients with washout period < 6 weeks from the last dose of ipilimumab or other
             immunotherapy

          8. Known positive serology for HIV, active hepatitis B, and/or active hepatitis C
             infection

          9. Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,
             inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal
             muscular atrophy)

         10. Patients who are planning on embarking on a new strenuous exercise regimen after first
             dose of study treatment. Muscular activities, such as strenuous exercise, that can
             result in significant increases in plasma CK levels should be avoided while on MEK162
             treatment

         11. Patients currently receiving treatment with strong CYP3A4 inhibitors who cannot
             discontinue such treatment or be switched to a different medication prior to starting
             study drug are excluded from study entry. Strong CYP3A4 inhibitors include the
             following medications: itraconazole, ketoconazole, miconazole, voriconazole;
             amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir;
             ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine,
             nefazodone, nicardipine, propofol, quinidine, telithromycin.

         12. Patients receiving treatment with any medications that have the potential to prolong
             the QT interval who cannot discontinue such treatment or be switched to a different
             medication prior to starting study drug are excluded from the study entry. A list of
             anti-arrhythmic drugs and other drugs that may prolong the QT interval is added in
             protocol section 8.5 (page 53).

         13. Impaired gastrointestinal (GI) function or active GI disease that may significantly
             alter the absorption of study drug in the opinion of the treating physician (e.g.,
             active ulcerative diseases, uncontrolled nausea, uncontrolled vomiting, uncontrolled
             diarrhea, active malabsorption syndrome, small bowel resection within last 1 year or
             gastric bypass surgery within last 1 year).

         14. Another active primary malignant disease, which requires systemic treatment
             (chemotherapy or radiation)

         15. History of significant congenital or acquired bleeding disorder unrelated to cancer

         16. Major surgery within 4 weeks prior to Day 1 of the study or who have not recovered
             from prior surgery.

         17. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test

         18. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             throughout the study and for 3 months after study drug discontinuation. Highly
             effective methods of contraception are further defined.

         19. Patients who are eligible, willing and able to receive an allogeneic stem cell
             transplant within 6 weeks are not eligible.

         20. Sexually active males unless they use a condom during intercourse while taking the
             drug and for 3 months after stopping treatment and should not father a child in this
             period. A condom is required to be used also by vasectomized men in order to prevent
             delivery of the drug via seminal fluid;

         21. History of non-compliance to medical regimens or inability to grant consent.